Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles...
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch Focusing on partnership model for MicroDose-MN™ and...
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products Leading U.S.-based CDMO to manufacture PharmaTher's proprietary ketamine products for FDA Phase 3...
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome Achieving its second FDA orphan drug designation with ketamine.Building a proprietary...
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund TORONTO, September 21, 2021 -- InvestorsHub NewsWire -- PharmaTher Holdings Ltd. (the...
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 10 clinical sites selected to participate in the FDA Phase 2 clinical...
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis Focusing on becoming a global leader in prescription-based ketamine productsAdvancing to a Phase...
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation Strengthens position to become a leader in the intradermal delivery of FDA...
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression Potential for FDA 505(b)(2) regulatory pathway approval and...
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease TORONTO, May 25, 2021 -- InvestorsHub NewsWire -- PharmaTher Holdings...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.02 | 8.88888888889 | 0.225 | 0.245 | 0.205 | 60100 | 0.21352589 | CS |
| 4 | 0.04 | 19.512195122 | 0.205 | 0.25 | 0.2 | 111668 | 0.22275504 | CS |
| 12 | 0.03 | 13.9534883721 | 0.215 | 0.33 | 0.18 | 114189 | 0.2444643 | CS |
| 26 | 0.025 | 11.3636363636 | 0.22 | 0.33 | 0.18 | 74289 | 0.23648217 | CS |
| 52 | 0.105 | 75 | 0.14 | 0.43 | 0.14 | 86579 | 0.24828668 | CS |
| 156 | -0.105 | -30 | 0.35 | 0.48 | 0.055 | 105226 | 0.19606342 | CS |
| 260 | -0.01 | -3.92156862745 | 0.255 | 1.24 | 0.05 | 204098 | 0.34954143 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
